JP7455141B2 - アポトーシスタンパク質の阻害剤の二価拮抗薬 - Google Patents
アポトーシスタンパク質の阻害剤の二価拮抗薬 Download PDFInfo
- Publication number
- JP7455141B2 JP7455141B2 JP2021560419A JP2021560419A JP7455141B2 JP 7455141 B2 JP7455141 B2 JP 7455141B2 JP 2021560419 A JP2021560419 A JP 2021560419A JP 2021560419 A JP2021560419 A JP 2021560419A JP 7455141 B2 JP7455141 B2 JP 7455141B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- mmol
- tetrahydronaphthalen
- pyrrolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004169 proteins and genes Human genes 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 title description 6
- 230000006907 apoptotic process Effects 0.000 title description 5
- 239000003112 inhibitor Substances 0.000 title description 4
- 239000005557 antagonist Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 419
- -1 heteroalkenylene Chemical group 0.000 claims description 151
- 239000000203 mixture Substances 0.000 claims description 151
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
- 125000005647 linker group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000006239 protecting group Chemical group 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 230000001404 mediated effect Effects 0.000 claims description 22
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 19
- 208000036142 Viral infection Diseases 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 230000009385 viral infection Effects 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 13
- 125000000732 arylene group Chemical group 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 201000002628 peritoneum cancer Diseases 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 8
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 208000002672 hepatitis B Diseases 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 125000005549 heteroarylene group Chemical group 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 127
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 122
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 102
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 68
- 238000006243 chemical reaction Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 59
- 239000007787 solid Substances 0.000 description 56
- 235000019439 ethyl acetate Nutrition 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- 239000000706 filtrate Substances 0.000 description 43
- 238000003818 flash chromatography Methods 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 38
- 238000000034 method Methods 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 239000012267 brine Substances 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- QKNFFJHHPCWXTH-VKHMYHEASA-N (2s)-2-(methylamino)propanamide Chemical compound CN[C@@H](C)C(N)=O QKNFFJHHPCWXTH-VKHMYHEASA-N 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 239000007821 HATU Substances 0.000 description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 230000002441 reversible effect Effects 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 10
- 108091007065 BIRCs Proteins 0.000 description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004043 oxo group Chemical group O=* 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 125000004404 heteroalkyl group Chemical group 0.000 description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 7
- ZYOIOWSPJZAYEL-CYBMUJFWSA-N tert-butyl n-[(1r)-5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl]carbamate Chemical compound C1=CC=C2[C@H](NC(=O)OC(C)(C)C)CCCC2=C1Br ZYOIOWSPJZAYEL-CYBMUJFWSA-N 0.000 description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 5
- 125000002015 acyclic group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000007942 carboxylates Chemical group 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- ZBONQSYJIGEGCQ-CYBMUJFWSA-N (5R)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid Chemical compound CC(C)(C)OC(N[C@H](CCC1)C2=C1C(C(O)=O)=CC=C2)=O ZBONQSYJIGEGCQ-CYBMUJFWSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- SZLPTIRUVOEEEO-UHFFFAOYSA-N 2-[4-[2-(4-methylphenyl)sulfonyloxyethyl]phenyl]ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCC1=CC=C(CCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1 SZLPTIRUVOEEEO-UHFFFAOYSA-N 0.000 description 3
- DZVSAHOHDQUFMZ-UHFFFAOYSA-N 2-hydroxyethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCO)C=C1 DZVSAHOHDQUFMZ-UHFFFAOYSA-N 0.000 description 3
- QRAOZQGIUIDZQZ-UHFFFAOYSA-N 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical compound C=1C=C2N(C)CCOC2=CC=1B1OC(C)(C)C(C)(C)O1 QRAOZQGIUIDZQZ-UHFFFAOYSA-N 0.000 description 3
- NIKCQOSXQMMUAA-ROJLCIKYSA-N CC(C)(C)OC(N[C@H]1C2=CC=CC(C(C=C3)=CC=C3C3=CC=CC4=C3CCC[C@H]4NC(OC(C)(C)C)=O)=C2CCC1)=O Chemical compound CC(C)(C)OC(N[C@H]1C2=CC=CC(C(C=C3)=CC=C3C3=CC=CC4=C3CCC[C@H]4NC(OC(C)(C)C)=O)=C2CCC1)=O NIKCQOSXQMMUAA-ROJLCIKYSA-N 0.000 description 3
- VFRPBAZPWOTFSA-FQLXRVMXSA-N CC(C)(C)OC(N[C@H]1C2=CC=CC(OCCCCCOC3=CC=CC4=C3CCC[C@H]4NC(OC(C)(C)C)=O)=C2CCC1)=O Chemical compound CC(C)(C)OC(N[C@H]1C2=CC=CC(OCCCCCOC3=CC=CC4=C3CCC[C@H]4NC(OC(C)(C)C)=O)=C2CCC1)=O VFRPBAZPWOTFSA-FQLXRVMXSA-N 0.000 description 3
- VAFRMBCNJNSDDZ-ROJLCIKYSA-N CC(C)(C)OC(N[C@H]1C2=CC=CC(OCCN3CCN(CCOC4=CC=CC5=C4CCC[C@H]5NC(OC(C)(C)C)=O)CC3)=C2CCC1)=O Chemical compound CC(C)(C)OC(N[C@H]1C2=CC=CC(OCCN3CCN(CCOC4=CC=CC5=C4CCC[C@H]5NC(OC(C)(C)C)=O)CC3)=C2CCC1)=O VAFRMBCNJNSDDZ-ROJLCIKYSA-N 0.000 description 3
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- ZWRPOGCKZPXNRU-GDLZYMKVSA-N benzyl N-[(1R)-5-(benzhydrylideneamino)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamate Chemical compound O=C(N[C@H]1C2=CC=CC(N=C(C3=CC=CC=C3)C3=CC=CC=C3)=C2CCC1)OCC1=CC=CC=C1 ZWRPOGCKZPXNRU-GDLZYMKVSA-N 0.000 description 3
- WTBLXOZXVRGWQS-QGZVFWFLSA-N benzyl N-[(1R)-5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl]carbamate Chemical compound O=C(N[C@H]1C2=CC=CC(Br)=C2CCC1)OCC1=CC=CC=C1 WTBLXOZXVRGWQS-QGZVFWFLSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000002875 fluorescence polarization Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229940013688 formic acid Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- MSXYIMKCOGBHRU-CQSZACIVSA-N methyl (5R)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylate Chemical compound CC(C)(C)OC(N[C@H](CCC1)C2=C1C(C(OC)=O)=CC=C2)=O MSXYIMKCOGBHRU-CQSZACIVSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DANSWGFXJWITDU-KBPBESRZSA-N tert-butyl (2S)-1-[(2S)-2-amino-2-cyclohexylacetyl]pyrrolidine-2-carboxylate Chemical compound CC(C)(C)OC([C@H](CCC1)N1C([C@H](C1CCCCC1)N)=O)=O DANSWGFXJWITDU-KBPBESRZSA-N 0.000 description 3
- KYTLCUZPDSFGPR-MRXNPFEDSA-N tert-butyl n-[(1r)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C([C@H]1NC(=O)OC(C)(C)C)CC2=C1C=CC=C2B1OC(C)(C)C(C)(C)O1 KYTLCUZPDSFGPR-MRXNPFEDSA-N 0.000 description 3
- KAHIZLGGWIWOGJ-GFCCVEGCSA-N tert-butyl n-[(1r)-4-bromo-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C1=CC=C(Br)C2=C1[C@H](NC(=O)OC(C)(C)C)CC2 KAHIZLGGWIWOGJ-GFCCVEGCSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- JUESDURRKGSJFK-YPNRBUGDSA-N (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1R)-5-[4-[(5R)-5-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5,6,7,8-tetrahydronaphthalen-1-yl]piperazin-1-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]pyrrolidine-2-carboxamide Chemical compound C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H]3CCCC4=C3C=CC=C4N5CCN(CC5)C6=CC=CC7=C6CCC[C@H]7NC(=O)[C@@H]8CCCN8C(=O)[C@H](C9CCCCC9)NC(=O)[C@H](C)NC)NC JUESDURRKGSJFK-YPNRBUGDSA-N 0.000 description 2
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical compound COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 description 2
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalene Chemical compound C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 2
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 2
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 2
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- NUCFKZASNPIMTD-SFTDATJTSA-N CC(C)(C)OC([C@H](CCC1)N1C([C@H](C1CCCCC1)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound CC(C)(C)OC([C@H](CCC1)N1C([C@H](C1CCCCC1)NC(OCC1=CC=CC=C1)=O)=O)=O NUCFKZASNPIMTD-SFTDATJTSA-N 0.000 description 2
- FEYXERMLCISRBK-BSBMHXFLSA-N CC[C@@H](C(N(CCC1)[C@@H]1C(N[C@H](CC1)C2=C1C(C1=CC=CC3=C1CC[C@H]3NC([C@H](CCC1)N1C([C@H](CC)NC([C@H](C)NC)=O)=O)=O)=CC=C2)=O)=O)NC([C@H](C)NC)=O Chemical compound CC[C@@H](C(N(CCC1)[C@@H]1C(N[C@H](CC1)C2=C1C(C1=CC=CC3=C1CC[C@H]3NC([C@H](CCC1)N1C([C@H](CC)NC([C@H](C)NC)=O)=O)=O)=CC=C2)=O)=O)NC([C@H](C)NC)=O FEYXERMLCISRBK-BSBMHXFLSA-N 0.000 description 2
- RUADJIXATTZQBI-OMEBYKIISA-N CC[C@@H](C(N(CCC1)[C@@H]1C(N[C@H]1C2=CC=CC(NC3=C(CCC[C@H]4NC([C@H](CCC5)N5C([C@H](CC)NC([C@H](C)NC)=O)=O)=O)C4=CC=C3)=C2CCC1)=O)=O)NC([C@H](C)NC)=O Chemical compound CC[C@@H](C(N(CCC1)[C@@H]1C(N[C@H]1C2=CC=CC(NC3=C(CCC[C@H]4NC([C@H](CCC5)N5C([C@H](CC)NC([C@H](C)NC)=O)=O)=O)C4=CC=C3)=C2CCC1)=O)=O)NC([C@H](C)NC)=O RUADJIXATTZQBI-OMEBYKIISA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 2
- RJRIDUZKERMABD-GFCCVEGCSA-N OC1=C2CCC[C@H](C2=CC=C1)NC(OC(C)(C)C)=O Chemical compound OC1=C2CCC[C@H](C2=CC=C1)NC(OC(C)(C)C)=O RJRIDUZKERMABD-GFCCVEGCSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- BMILJIGWVPMPNI-SFTDATJTSA-N benzyl (2S)-1-[(2S)-2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]pyrrolidine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)N1[C@@H](CCC1)C(=O)OCC1=CC=CC=C1)C1CCCCC1 BMILJIGWVPMPNI-SFTDATJTSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- ZXSBDSGRQIWJPM-UHFFFAOYSA-N dimethylcarbamothioic s-acid Chemical compound CN(C)C(S)=O ZXSBDSGRQIWJPM-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical group COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- KDQTYYDFAPUQKA-CYBMUJFWSA-N tert-butyl N-[(1R)-5-carbamoyl-1,2,3,4-tetrahydronaphthalen-1-yl]carbamate Chemical compound CC(C)(C)OC(N[C@H]1C2=CC=CC(C(N)=O)=C2CCC1)=O KDQTYYDFAPUQKA-CYBMUJFWSA-N 0.000 description 2
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QGEQKVZQPWSOTI-VIFPVBQESA-N (2s)-2-[methyl(phenylmethoxycarbonyl)amino]propanoic acid Chemical compound OC(=O)[C@H](C)N(C)C(=O)OCC1=CC=CC=C1 QGEQKVZQPWSOTI-VIFPVBQESA-N 0.000 description 1
- VLHQXRIIQSTJCQ-LURJTMIESA-N (2s)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)N(C)C(=O)OC(C)(C)C VLHQXRIIQSTJCQ-LURJTMIESA-N 0.000 description 1
- KZEDPVFJLQLDIZ-UHFFFAOYSA-N (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZEDPVFJLQLDIZ-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 1
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
- ARARQWKFKMWCDL-UHFFFAOYSA-N 1-nitro-2-[(2-nitrophenyl)methoxymethyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1COCC1=CC=CC=C1[N+]([O-])=O ARARQWKFKMWCDL-UHFFFAOYSA-N 0.000 description 1
- VJJRVNGOHNKPHB-UHFFFAOYSA-N 1-nitro-4-[(4-nitrophenyl)methoxymethyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1COCC1=CC=C([N+]([O-])=O)C=C1 VJJRVNGOHNKPHB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- VYVPNTJBGPQTFA-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 VYVPNTJBGPQTFA-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 description 1
- 101100347612 Arabidopsis thaliana VIII-B gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 1
- GMSYNKGBAOAPDV-WDTPKOOYSA-N CC(C)(C)OC(N[C@H]1C2=CC=CC(N(C3)CC(C4)C3CN4C3=CC=CC4=C3CCC[C@H]4NC(OC(C)(C)C)=O)=C2CCC1)=O Chemical compound CC(C)(C)OC(N[C@H]1C2=CC=CC(N(C3)CC(C4)C3CN4C3=CC=CC4=C3CCC[C@H]4NC(OC(C)(C)C)=O)=C2CCC1)=O GMSYNKGBAOAPDV-WDTPKOOYSA-N 0.000 description 1
- YPVSLRPEHBICMT-JTTJXQCZSA-N CC(C)(C)OC(N[C@H]1C2=CC=CC(N3CC(CNC4)C4C3)=C2CCC1)=O Chemical compound CC(C)(C)OC(N[C@H]1C2=CC=CC(N3CC(CNC4)C4C3)=C2CCC1)=O YPVSLRPEHBICMT-JTTJXQCZSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- KKLYVSSQSTWQBV-QZTJIDSGSA-N N[C@H](CCC1)C2=C1C(NC1=CC=CC3=C1CCC[C@H]3N)=CC=C2 Chemical compound N[C@H](CCC1)C2=C1C(NC1=CC=CC3=C1CCC[C@H]3N)=CC=C2 KKLYVSSQSTWQBV-QZTJIDSGSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical group ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- BKPXSJVUZWYLAT-CYBMUJFWSA-N [(5R)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-5,6,7,8-tetrahydronaphthalen-1-yl]boronic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H]1C=2C=CC=C(C=2CCC1)B(O)O BKPXSJVUZWYLAT-CYBMUJFWSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- MESWOAINMZIETA-ROUUACIJSA-N benzyl (2S)-1-[(2S)-2-amino-2-cyclohexylacetyl]pyrrolidine-2-carboxylate Chemical compound N[C@H](C(=O)N1[C@@H](CCC1)C(=O)OCC1=CC=CC=C1)C1CCCCC1 MESWOAINMZIETA-ROUUACIJSA-N 0.000 description 1
- UCFYLJUOABBAQX-OYDLWJJNSA-N benzyl (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoyl]amino]acetyl]pyrrolidine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)N([C@H](C(=O)N[C@H](C(=O)N1[C@@H](CCC1)C(=O)OCC1=CC=CC=C1)C1CCCCC1)C)C UCFYLJUOABBAQX-OYDLWJJNSA-N 0.000 description 1
- VVCLBQFBKZQOAF-NSHDSACASA-N benzyl (2s)-pyrrolidine-2-carboxylate Chemical compound O=C([C@H]1NCCC1)OCC1=CC=CC=C1 VVCLBQFBKZQOAF-NSHDSACASA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002443 hydroxylamines Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KOUCTZDKTJGHSS-UHFFFAOYSA-N pentyl 4-methylbenzenesulfonate Chemical compound CCCCCOS(=O)(=O)C1=CC=C(C)C=C1 KOUCTZDKTJGHSS-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005750 substituted cyclic group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XJJBXZIKXFOMLP-ZETCQYMHSA-N tert-butyl (2s)-pyrrolidine-2-carboxylate Chemical compound CC(C)(C)OC(=O)[C@@H]1CCCN1 XJJBXZIKXFOMLP-ZETCQYMHSA-N 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 150000003673 urethanes Chemical group 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Description
2019年4月5日に出願された米国優先権出願第62/830031号は、明細書、図面、特許請求の範囲、および要約を含めて、その全体が参照により本明細書に組み込まれる。2019年4月8日に出願された米国優先権出願第62/831155号は、明細書、図面、特許請求の範囲、および要約を含めて、その全体が参照により本明細書に組み込まれる。
本技術は、宿主細胞IAP(cIAP)を含むアポトーシスタンパク質の阻害剤(IAP)に拮抗することに関連する化合物、組成物、および方法に関する。具体的には、本発明の化合物および組成物は、例えば、卵巣がんを含む様々ながんおよび慢性B型肝炎感染を治療するために使用され得る。
プログラム細胞死とも称されるアポトーシスは、多細胞生物で発生する重要かつ高度に制御された細胞プロセスであり、アポトーシス機能不全は、ヒトのがんの特徴である。アポトーシスタンパク質1および2の細胞阻害剤(cIAP1およびcIAP2)ならびにアポトーシスタンパク質のX連鎖阻害剤(XIAP)などのアポトーシスタンパク質の阻害剤(IAP)は、新しいクラスのがん治療の魅力的な標的として特定されている。
一態様では、本技術は、式Iによる化合物、その立体異性体、またはこの化合物もしくはこの化合物の立体異性体の薬学的に許容される塩であって、
式中、
Xは、O、NR6、またはCH2であり、
qは、0、1、または2であり、
R1およびR2は、各出現において、独立して、置換もしくは非置換のC1~6アルキル、C3~6シクロアルキル、アリール、アラルキル、ヘテロシクリル、またはヘテロシクリルアルキル基から選択され、
R3およびR4は、各出現において、独立して、H、アミノ保護基、または置換もしくは非置換のC1~6アルキル基であり、
R5は、各出現において、独立して、H、F、NH2、OH、NH-(アミノ保護基)、またはO-(ヒドロキシル保護基)であり、
R6は、各出現において、独立して、H、置換もしくは非置換のC1~6アルキル、C3~6シクロアルキル基、またはアミノ保護基であり、
リンカーは、結合、オキシ部分、または、アミノ、アルキレン、ヘテロアルキレン、アルケニレン、ヘテロアルケニレン、アルキニレン、ヘテロアルキニレン、シクロアルキレン、シクロアルキルヘテロアルキレン、アリーレン、アラルキレン、アリールヘテロアルキレン、ヘテロシクリレン、ヘテロシクリルアルキレン、ヘテロシクリルヘテロアルキレン、ヘテロアリーレン、ヘテロアリールアルキレン、およびヘテロアリールヘテロアルキレンからなる群から選択される置換されていてもよい部分から選択される二価部分である、式Iの化合物、その立体異性体、またはこの化合物もしくはこの化合物の立体異性体の薬学的に許容される塩を提供する。
R1およびR2は、独立して、置換もしくは非置換のC1~6アルキル、C3~6シクロアルキル、アリール、アラルキル、ヘテロシクリル、またはヘテロシクリルアルキル基から選択され、
R3およびR4は、独立して、H、アミノ保護基、または置換もしくは非置換のC1~6アルキル基であり、
R5は、H、F、NH2、OH、NH-(アミノ保護基)、またはO-(ヒドロキシル保護基)であり、
R6は、H、置換もしくは非置換のC1~6アルキル、C3~6シクロアルキル基、またはアミノ保護基であり、
リンカーは、二価であり、結合、アミノ、オキシ、アルキレン、ヘテロアルキレン、アルケニレン、ヘテロアルケニレン、アルキニレン、ヘテロアルキニレン、シクロアルキレン、シクロアルキルヘテロアルキレン、アリーレン、アリールアルキレン、アリールヘテロアルキレン、ヘテロシクリレン、ヘテロシクリルアルキレン、ヘテロシクリルヘテロアルキレン、ヘテロアリーレン、ヘテロアリールアルキレン、およびヘテロアリールヘテロアルキレンからなる群から選択される。
[本発明1001]
式Iの化合物、その立体異性体、または前記化合物もしくは前記化合物の前記立体異性体の薬学的に許容される塩であって、
式中、
Xが、O、NR 6 、またはCH 2 であり、
qが、0、1、または2であり、
R 1 およびR 2 が、各出現において、独立して、置換もしくは非置換のC 1~6 アルキル、C 3~6 シクロアルキル、アリール、アラルキル、ヘテロシクリル、またはヘテロシクリルアルキル基から選択され、
R 3 およびR 4 が、各出現において、独立して、H、アミノ保護基、または置換もしくは非置換のC 1~6 アルキル基であり、
R 5 が、各出現において、独立して、H、F、NH 2 、OH、NH-(アミノ保護基)、またはO-(ヒドロキシル保護基)であり、
R 6 が、各出現において、独立して、H、置換もしくは非置換のC 1~6 アルキル、C 3~6 シクロアルキル基、またはアミノ保護基であり、
リンカーが、結合、オキシ部分、または、アミノ、アルキレン、ヘテロアルキレン、アルケニレン、ヘテロアルケニレン、アルキニレン、ヘテロアルキニレン、シクロアルキレン、シクロアルキルヘテロアルキレン、アリーレン、アラルキレン、アリールヘテロアルキレン、ヘテロシクリレン、ヘテロシクリルアルキレン、ヘテロシクリルヘテロアルキレン、ヘテロアリーレン、ヘテロアリールアルキレン、およびヘテロアリールヘテロアルキレンからなる群から選択される置換されていてもよい部分から選択される二価部分である、
式Iの化合物、その立体異性体、または前記化合物もしくは前記化合物の前記立体異性体の薬学的に許容される塩。
[本発明1002]
リンカーが、ヘテロアルキレン、アリーレン、アラルキレン、アリールヘテロアルキレン、ヘテロシクリルアルキレン、およびヘテロシクリルヘテロアルキレンからなる群から選択される、本発明1001の化合物。
[本発明1003]
リンカーが、C 2 ~C 12 ポリアルキレンオキシド、フェニルアルキレン、フェニルヘテロアルキレン、ピペラジニルアルキレン、およびピペラジニルヘテロアルキレンからなる群から選択される、本発明1001または本発明1002の化合物。
[本発明1004]
リンカーが、結合、
からなる群から選択され、式中、
mが、0、1、2、3、4、5、または6であり、
nが、1、2、3、4、5、6である、
本発明1001の化合物。
[本発明1005]
nが、1、2、または3であり、mが、0、1、2、3、または4である、本発明1004の化合物。
[本発明1006]
リンカーが、
であり、
nが、2または3である、
本発明1001~1005のいずれかの化合物。
[本発明1007]
リンカーが、結合、-NH-、または-C(O)NH-である、本発明1001~1005のいずれかの化合物。
[本発明1008]
リンカーが、
である、本発明1001の化合物。
[本発明1009]
mが、1、2、3、または4である、本発明1008の化合物。
[本発明1010]
リンカーが、
である、本発明1001の化合物。
[本発明1011]
nが、2または3である、本発明1010の化合物。
[本発明1012]
リンカーが、
であり、式中、mが、0または1である、本発明1001の化合物。
[本発明1013]
R 1 およびR 2 が、独立して、メチル、エチル、n-プロピル、i-プロピル、n-ブチル、s-ブチル、i-ブチル、t-ブチル、シクロプロピル、シクロブチル、シクロヘキシル、およびシクロペンチル基からなる群から選択される、本発明1001~1012のいずれかの化合物。
[本発明1014]
R 3 が、メチル、エチル、n-プロピル、i-プロピル、n-ブチル、i-ブチル、またはt-ブチル基である、本発明1001~1013のいずれかの化合物。
[本発明1015]
R 4 が、アミノ保護基である、本発明1001~1014のいずれかの化合物。
[本発明1016]
R 4 が、Hである、本発明1001~1014のいずれかの化合物。
[本発明1017]
R 5 が、Hである、本発明1001~1016のいずれかの化合物。
[本発明1018]
Xが、CH 2 またはOである、本発明1001~1017のいずれかの化合物。
[本発明1019]
qが、0または1である、本発明1001~1018のいずれかの化合物。
[本発明1020]
式IA:
の構造、その立体異性体、または前記化合物もしくは前記化合物の前記立体異性体の薬学的に許容される塩を有する、本発明1001~1017のいずれかの化合物。
[本発明1021]
R 2 が、メチルである、本発明1020の化合物。
[本発明1022]
R 1 が、シクロヘキシルまたはイソプロピルである、本発明1020または1021の化合物。
[本発明1023]
R 3 が、メチルである、本発明1020~1022のいずれかの化合物。
[本発明1024]
R 4 が、Hである、本発明1020~1023のいずれかの化合物。
[本発明1025]
R 5 が、Hである、本発明1020~1024のいずれかの化合物。
[本発明1026]
表Iの任意の化合物から選択される、本発明1001の化合物。
[本発明1027]
本発明1001~1026のいずれかの化合物と、薬学的に許容される担体とを含む、組成物。
[本発明1028]
IAPによって媒介されるがんまたはウイルス感染を治療するための、本発明1001~1026のいずれかの化合物の有効量を含む、薬学的組成物。
[本発明1029]
IAPによって媒介される前記がんまたはウイルス感染が、卵巣がん、卵管がん、腹膜がん、およびB型肝炎感染からなる群から選択される、本発明1028の薬学的組成物。
[本発明1030]
IAPによって媒介されるがんまたはウイルス感染に罹患している対象に、本発明1001~1026のいずれかの化合物の有効量を投与する工程、または本発明1001~1026のいずれかの化合物の有効量を含む薬学的組成物を投与する工程を含む、治療方法。
[本発明1031]
前記がんまたはウイルス感染が、卵巣がん、卵管がん、腹膜がん、およびB型肝炎感染からなる群から選択される、本発明1030の方法。
様々な態様では、本技術は、cIAPの作用を拮抗するための、ならびにcIAP媒介性障害および状態の治療のための化合物および方法を提供する。本明細書で提供される化合物は、開示される方法において有用な薬学的組成物および薬剤に製剤化することができる。薬学的製剤および薬剤の調製における化合物の使用も提供される。
のような二価のヘテロシクリルヘテロアルキレンは、基の各ヘテロアルキレン部分に結合点を有し得るか、またはヘテロアルキレン部分に1つの結合点を有し、ヘテロシクリル部分に別の結合点を有し得る。非環式基で置換されているが環系に両方の結合点を有する二価の環状基は、置換されている環状エンである。例えば、位置1および4に結合点を持つ2-メチルフェニル基は、アリーレンであり、アリールアルキレンではない。
変数リンカー、X、q、R1、R2、R3、R4、およびR5は、本明細書に開示される値のいずれかを有するものとして定義され得る。
からなる群から選択され得、式中、
mが、0、1、2、3、4、5、または6であり、
nが、1、2、3、4、5、6である。
全ての試薬および材料は、商業的製造供給元から購入されるか、または購入された。
以下の化合物は、当業者に知られている手順を使用して、以下の合成スキームに示されるように調製された、または調製することができる。
ACN アセトニトリル
AcOH 酢酸
Ad2PBu ブチルジ-1-アダマンチルホスフィン
t-Bu tert-ブチル
t-BuXPhos 2-ジ-tert-ブチルホスフィノ-2’,4’,6’-トリイソプロピルビフェニル
CDI 1,1’-カルボニルジイミダゾール
DCM ジクロロメタン
DIAD アゾジカルボン酸ジイソプロピル
DMF ジメチルホルムアミド
DMA ジメチルアセトアミド
DMAP 4-ジメチルアミノピリジン
DMP tert-2,2-ジメトキシプロパン
DMSO ジメチルスルホキシド
EDC 3-(エチルイミノメチレンアミノ)-N、N-ジメチルプロパン-1-アミン
Et エチル
HATU(1-[ビス(ジメチルアミノ)メチレン]-1H-1,2,3-トリアゾロ[4,5-b]ピリジニウム3-オキシドヘキサフルオロホスフェート)
LAH 水素化アルミニウムリチウム
Me メチル
MeCN アセトニトリル
NCS N-クロロスクシンイミド
PCC ピリジニウムクロロクロメート
Pd2(dba)3 トリス(ジベンジリデンアセトン)ジパラジウム
Pd(dppf)Cl2 [1,1’-ビス(ジフェニルホスフィノ)フェロセン]二塩化パラジウム(II)
PE 石油エーテル
Ph フェニル
Py ピリジン
Ruphos 2-ジシクロヘキシルホスフィノ-2’、6’-ジイソプロポキシ-1,1’-ビフェニル
STAB トリアセトキシ水素化ホウ素ナトリウム
TEA トリエチルアミン
TFA トリフルオロ酢酸
TFAA トリフルオロ酢酸無水物
THF テトラヒドロフラン
TLC 薄層クロマトグラフィー
TMS トリメチルシリル
TsCl p-トルエンスルホニルクロリド
TsOH p-トルエンスルホン酸
Xantphos 4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン
LCMS(ESI,m/z):[M+H]+=1041.6.1H NMR(300 MHz,DMSO-d6):δ 8.22-8.09(m,2H),8.01-7.89(m,2H),7.18-7.03(m,2H),6.91-6.77(m,4H),4.99-4.80(m,2H),4.60-4.45(m,2H),4.40-4.27(m,2H),4.07-3.94(m,4H),3.93-3.53(m,8H),3.30-3.18(m,4H),3.05-2.91(m,2H),2.69-2.55(m,4H),2.25-2.14(m,6H),2.12-1.89(m,8H),1.89-1.53(m,22H),1.39-1.19(m,4H),1.17-1.05(m,6H)。
LCMS(ESI,m/z):[M+H]+=1069.9.1H NMR(300 MHz,DMSO-d6):δ 8.30-8.14(m,2H),7.99-7.86(m,2H),7.15-7.01(m,2H),6.95-6.85(m,2H),6.84-6.77(m,2H),5.47-5.35(m,2H),4.98-4.81(m,2H),4.42-4.30(m,4H),4.28-4.18(m,2H),4.07-3.96(m,4H),3.95-3.83(m,2H),3.50-3.40(m,4H),3.05-2.94(m,2H),2.68-2.56(m,4H),2.37-2.24(m,2H),2.23-2.13(m,6H),1.90-1.55(m,28H),1.18-0.90(m,16H)。
LCMS(ESI,m/z):[M+H]+=901.5.1H NMR(300 MHz,DMSO-d6):δ 8.55-7.86(m,4H),7.21-7.00(m,2H),6.99-6.67(m,4H),5.02-4.75(m,2H),4.73-4.48(m,2H),4.47-4.19(m,2H),4.11-3.87(m,4H),3.67-3.55(m,2H),3.03-2.83(m,2H),3.72-2.55(m,4H),2.32-1.50(m,32H),1.32-1.00(m,12H)。
LCMS(ESI,m/z):[M+H]+=929.7.1H NMR(300 MHz,DMSO-d6):δ 8.50-8.05(m,2H),8.01-7.83(m,2H),7.17-7.04(m,2H),6.90-6.77(m,4H),4.98-4.85(m,2H),4.59-4.46(m,2H),4.40-4.29(m,2H),4.09-3.91(m,4H),3.73-3.50(m,4H),3.03-2.89(m,2H),2.67-2.56(m,4H),2.18(s,6H),2.14-1.49(m,28H),1.19-1.05(m,6H),0.97-0.78(m,6H)。
LCMS(ESI,m/z):[M+H]+=1053.6.1H NMR(300 MHz,DMSO-d6):δ 8.28-8.17(m,2H),8.01-7.86(m,2H),7.15-7.02(m,2H),6.96-6.88(m,2H),6.87-6.79(m,2H),6.10-6.03(m,2H),5.52-5.42(m,2H),4.98-4.85(m,2H),4.65-4.55(m,4H),4.45-4.28(m,4H),4.27-4.18(m,2H),3.93-3.85(m,2H),3.53-3.43(m,2H),3.07-2.96(m,2H),2.67-2.57(m,4H),2.36-2.25(m,2H),2.18(s,6H),1.93-1.53(m,24H),1.22-0.95(m,16H)。
LCMS(ESI,m/z):[M+H]+=1071.7.1H NMR(400 MHz,DMSO-d6)δ 8.08(d,J=8.8 Hz,2H),7.84(d,J=8.8 Hz,2H),7.47(s,4H),7.16-7.04(m,2H),6.93-6.85(m,4H),5.11(s,4H),4.95-4.85(m,2H),4.47-4.38(m,2H),4.34-4.26(m,2H),3.77-3.67(m,2H),3.65-3.54(m,2H),2.99-2.89(m,2H),2.67-2.60(m,4H),2.20-2.16(m,7H),2.10-1.90(m,5H),1.89-1.76(m,10H),1.76-1.55(m,14H),1.18-0.88(m,16H)。
LCMS(ESI,m/z):[M+H]+=957.7.1H NMR(300 MHz,DMSO-d6):δ 8.20-8.09(m,2H),8.02-7.78(m,2H),7.17-7.00(m,2H),6.93-6.74(m,4H),4.98-4.81(m,2H),4.51-4.40(m,2H),4.38-4.27(m,2H),4.04-3.95(m,4H),3.74-3.60(m,6H),3.10-2.98(m,2H),2.67-2.55(m,4H),2.18(s,6H),2.10-1.59(m,24H),1.19-1.08(m,6H),0.99-0.78(m,12H)。
LCMS(ESI,m/z):[M+H]+=959.6.1H NMR(300 MHz,DMSO-d6,ppm):δ 8.38-8.13(m,2H),7.91-7.87(m,2H),7.13-7.04(m,2H),6.89-6.79(m,4H),4.95-4.80(m,2H),4.45-4.28(m,4H),4.12-4.07(m,4H),3.87-3.80(m,4H),3.69-3.51(m,4H),2.97-2.92(m,2H),2.58-2.50(m,4H),2.16(s,6H),2.02-1.57(m,20H),1.17-1.04(m,6H),0.97-0.75(m,12H)。
LCMS(ESI,m/z):[M+H]+=1043.5.1H NMR(300 MHz,DMSO-d6,ppm):δ 8.42-8.09(m,2H),7.97-7.73(m,2H),7.20-7.01(m,2H),6.91-6.76(m,4H),4.95-4.81(m,2H),4.54-4.43(m,2H),4.40-4.25(m,2H),4.15-4.03(m,4H),3.91-3.56(m,12H),3.30-3.15(m,4H),3.03-2.87(m,2H),2.64-2.53(m,4H),2.16(s,6H),2.10-1.90(m,8H),1.89-1.72(m,8H),1.72-1.49(m,8H),1.45-1.19(m,4H),1.17-1.00(m,6H)。
LCMS(ESI,m/z):[M+H]+=1071.7.1H NMR(300 MHz,DMSO-d6)δ 8.32-8.23(m,3H),8.16-7.90(m,2H),7.14-7.00(m,2H),6.98-6.87(m,2H),6.87-6.73(m,2H),4.95-4.80(m,2H),4.42-4.28(m,7H),4.23-4.01(m,5H),3.93-3.80(m,7H),3.50-3.40(m,2H),3.08-2.98(m,2H),2.61-2.55(m,3H),2.34-2.17(m,8H),1.89-1.49(m,23H),1.25-1.05(m,13H),1.05-0.81(m,4H)。
LCMS(ESI,m/z):[M+H]+=1039.7.1H NMR(400 MHz,DMSO-d6):δ 8.19(s,1H),8.04(d,J=8.4 Hz,2H),7.92(d,J=8.8 Hz,2H),7.14(d,J=8.4 Hz,2H),6.70-6.64(m,4H),4.90-4.80(m,2H),4.50-4.40(m,2H),4.39-4.21(m,2H),4.08-4.03(m,4H),3.79-3.68(m,6H),3.65-3.55(m,2H),3.10-2.95(m,2H),2.73-2.62(m,4H),2.19(s,6H),2.10-1.93(m,4H),1.90-1.55(m,26H),1.27-1.09(m,11H),1.08-0.88(m,5H)。
LCMS(ESI,m/z):[M+H]+=1039.7.1H NMR(300 MHz,DMSO-d6)δ 8.27-8.18(m,2H),7.87-7.69(m,2H),7.00-6.93(m,2H),6.87(d,J=2.1 Hz,2H),6.77-6.67(m,2H),4.97-4.85(m,2H),4.54-4.38(m,2H),4.33-4.16(m,4H),4.08-3.96(m,2H),3.87-3.70(m,6H),3.67-3.55(m,2H),3.01-2.89(m,2H),2.74-2.61(m,4H),2.17(s,6H),2.13-1.94(m,4H),1.92-1.51(m,25H),1.32-0.80(m,17H)。
LCMS(ESI,m/z):[M+H]+=1011.7.1H NMR(300 MHz,DMSO-d6)δ 8.22-8.05(m,4H),7.22-7.04(m,2H),6.90-6.78(m,4H),5.31-5.17(m,2H),4.53-4.37(m,2H),4.35-4.25(m,2H),4.20-4.05(m,4H),3.89-3.80(m,4H),3.79-3.57(m,4H),3.25-3.12(m,2H),2.94-2.79(m,2H),2.73-2.50(m,2H),2.40-2.28(m,2H),2.25(s,6H),2.13-1.91(m,4H),1.91-1.53(m,19H),1.24-0.87(m,17H)。
LCMS(ESI,m/z):[M+H]+=1011.7.1H NMR(300 MHz,DMSO-d6,ppm):δ 8.55-8.12(m,2H),7.93-7.72(m,2H),7.64-7.46(m,1H),7.37-7.08(m,9H),5.10-4.93(m,2H),4.54-4.39(m,2H),4.38-4.28(m,2H),3.81-3.55(m,4H),3.03-2.89(m,2H),2.70-2.55(m,4H),2.17(s,6H),2.11-1.93(m,6H),1.92-1.52(m,24H),1.28-0.88(m,16H)。
LCMS(ESI,m/z):[M+H]+=1062.6;1H NMR(300 MHz,DMSO-d6,ppm):δ 8.52-8.22(m,2H),8.00(d,J=8.4 Hz,2H),7.90-7.84(m,4H),7.52-7.42(m,2H),7.39-7.29(m,2H),7.29-7.21(m,2H),7.20-7.12(m,2H),5.08-4.95(m,2H),4.54-4.28(m,4H),3.81-3.55(m,4H),3.01-2.88(m,2H),2.71-2.55(m,4H),2.18(s,6H),2.12-1.93(m,6H),1.92-1.55(m,24H),1.26-0.84(m,16H)。
LCMS(ESI,m/z):[M+H]+=875.5.1H NMR(300 MHz,DMSO-d6)δ 8.66-8.17(m,2H),8.07-7.92(m,2H),7.55-7.46(m,1H),7.37-7.20(m,6H),7.18-7.08(m,3H),5.07-4.94(m,2H),4.65-4.52(m,2H),4.39-4.27(m,2H),3.72-3.50(m,4H),3.00-2.87(m,2H),2.70-2.55(m,4H),2.19(s,6H),2.13-1.57(m,18H),1.27-1.17(m,6H),1.14-1.05(m,6H)。
LCMS(ESI,m/z):[M+H]+=903.6.1H NMR(300 MHz,DMSO-d6)δ 8.62-8.24(m,2H),7.98-7.85(m,2H),7.53-7.45(m,1H),7.30-7.21(m,6H),7.16-7.11(m,3H),5.05-4.95(m,2H),4.54-4.30(m,4H),3.70-3.53(m,4H),2.99-2.90(m,2H),2.61-2.55(m,4H),2.22-2.18(m,6H),2.13-1.53(m,22H),1.15-1.09(m,6H),0.92-0.80(m,6H)。
LCMS(ESI,m/z):[M+H]+=931.7.1H NMR(300 MHz,DMSO-d6)δ 8.28(d,J=8.7 Hz,2H),7.94(d,J=9.0 Hz,2H),7.57-7.47(m,1H),7.34-7.10(m,9H),5.05-4.95(m,2H),4.47-4.39(m,2H),4.37-4.28(m,2H),3.82-3.48(m,4H),3.07-2.95(m,2H),2.71-2.57(m,4H),2.24-2.20(m,6H),2.13-1.97(m,6H),1.97-1.53(m,14H),1.18-1.11(m,6H),0.97-0.87(m,12H)。
LCMS(ESI,m/z):[M+H]+=959.6.1H NMR(300 MHz,DMSO-d6)δ 8.50-8.33(m,2H),7.86(d,J=9.6 Hz,2H),7.58-7.48(m,1H),7.43-7.33(m,2H),7.32-7.24(m,2H),7.24-7.08(m,5H),5.08-4.95(m,2H),4.61-4.48(m,2H),4.42-4.29(m,2H),3.81-3.59(m,4H),3.05-2.90(m,2H),2.68-2.57(m,4H),2.26-2.13(m,8H),2.13-1.98(m,4H),1.92-1.62(m,12H),1.20-1.10(m,6H),1.05(s,16H),0.92(s,2H)。
LCMS(ESI,m/z):[M+H]+=1088.3.1H NMR(300 MHz,DMSO-d6)δ 8.26(d,J=8.7 Hz,2H),7.89(d,J=9.0 Hz,2H),7.78(d,J=8.1 Hz,4H),7.40(d,J=8.1 Hz,4H),7.33(d,J=7.5 Hz,2H),7.26-7.21(m,2H),7.12(d,J=6.3 Hz,2H),5.10-4.95(m,2H),4.51-4.39(m,2H),4.39-4.29(m,2H),3.81-3.70(m,2H),3.70-3.56(m,2H),2.99-2.90(m,2H),2.71-2.55(m,4H),2.18(s,6H),2.10-1.93(m,4H),1.92-1.54(m,25H),1.28-0.87(m,17H)。
LCMS(ESI,m/z):[M+H]+=875.7.1H NMR(300 MHz,DMSO-d6):δ 8.32-8.16(m,2H),8.09-7.91(m,2H),7.41-7.21(m,8H),7.19-7.05(m,2H),5.09-4.96(m,2H),4.67-4.52(m,2H),4.49-4.29(m,2H),3.73-3.56(m,4H),3.04-2.89(m,2H),2.76-2.57(m,4H),2.27-2.18(m,6H),2.15-1.57(m,16H),1.32-1.19(m,6H),1.18-1.06(m,6H)。
LCMS(ESI,m/z):[M+H]+=903.8.1H NMR(300 MHz,DMSO-d6):δ 8.64-8.20(m,2H),8.03-7.84(m,2H),7.41-7.33(m,4H),7.33-7.21(m,4H),7.16-7.08(m,2H),5.12-4.93(m,2H),4.60-4.28(m,4H),3.81-3.39(m,4H),3.01-2.91(m,2H),2.71-2.55(m,4H),2.31-2.15(m,8H),2.11-1.52(m,20H),1.19-1.05(m,6H),0.97-0.80(m,6H)。
1H NMR(300 MHz,DMSO-d6):δ 8.50-8.35(m,2H),7.93-7.83(m,2H),7.43-7.35(m,6H),7.24-7.10(m,4H),5.12-4.91(m,2H),4.66-4.51(m,2H),4.45-4.29(m,2H),3.81-3.59(m,4H),3.06-2.90(m,2H),2.77-2.58(m,4H),2.26-2.00(m,12H),1.94-1.65(m,12H),1.19-1.09(m,6H),1.08-0.90(m,18H)。
LCMS(ESI,m/z):[M+H]+=1043.9.1H NMR(300 MHz,DMSO-d6):δ 8.35-8.30(m,2H),8.04-7.94(m,2H),7.44-7.28(m,6H),7.28-7.19(m,2H),7.17-7.07(m,2H),5.58-5.39(m,2H),5.13-4.97(m,2H),4.48-4.31(m,4H),4.31-4.18(m,2H),3.99-3.86(m,2H),3.56-3.45(m,2H),3.10-2.98(m,2H),2.70-2.59(m,4H),2.39-2.20(m,8H),2.08-1.40(m,24H),1.24-0.93(m,16H)。
LCMS(ESI,m/z):[M+H]+=1011.8.1H NMR(300 MHz,DMSO-d6)δ 8.50-8.15(m,2H),7.93-7.84(m,2H),7.80-7.69(m,4H),7.54-7.41(m,4H),7.40-7.29(m,2H),5.02-4.91(m,2H),4.52-4.40(m,2H),4.40-4.28(m,2H),3.81-3.70(m,2H),3.70-3.56(m,2H),3.02-2.90(m,2H),2.86-2.79(m,4H),2.17(s,6H),2.13-1.52(m,30H),1.28-0.90(m,16H)。
LCMS(ESI,m/z):[M+H]+=1011.6.1H NMR(300 MHz,DMSO-d6)δ 8.38-8.23(m,2H),7.91-7.81(m,6H),7.70-7.59(m,2H),7.58-7.45(m,2H),7.24-7.08(m,2H),5.04-4.94(m,2H),4.50-4.39(m,2H),4.39-4.29(m,2H),3.78-3.70(m,2H),3.70-3.58(m,2H),3.00-2.87(m,2H),2.82-2.74(m,4H),2.15(s,6H),2.15-1.95(m,6H),1.95-1.64(m,18H),1.60-1.41(m,6H),1.18-1.08(m,7H),1.08-0.85(m,9H)。
LCMS(ESI,m/z):[M+H]+=931.7.1H NMR(300 MHz,DMSO-d6):δ 8.60-8.26(m,2H),7.97-7.76(m,2H),7.44-7.31(m,6H),7.28-7.19(m,2H),7.16-7.08(m,2H),5.09-4.97(m,2H),4.56-4.40(m,2H),4.39-4.28(m,2H),3.79-3.50(m,4H),3.03-2.91(m,2H),2.69-2.54(m,4H),2.26-1.96(m,14H),1.95-1.76(m,8H),1.76-1.58(m,4H),1.19-1.04(m,6H),1.00-0.78(m,12H)。
LCMS(ESI,m/z):[M+H]+=1021.6.1H NMR(300 MHz,DMSO-d6,ppm):δ 8.50-8.09(m,2H),7.84-7.65(m,2H),7.10-7.05(m,2H),6.89-6.80(m,4H),6.07(s,2H),4.91-4.80(m,2H),4.50(s,4H),4.45-4.28(m,4H),3.71-3.60(m,4H),2.95-2.90(m,2H),2.69-2.53(m,4H),2.14(s,6H),2.10-1.91(m,4H),1.86-1.58(m,26H),1.18-0.94(m,16H)。
LCMS(ESI,m/z):[M+H]+=1019.6.1H NMR(300 MHz,DMSO-d6,ppm):δ 8.50-8.11(m,2H),7.88-7.65(m,2H),7.11-7.06(m,2H),6.93-6.84(m,4H),4.91-4.86(m,6H),4.46-4.40(m,2H),4.32-4.28(m,2H),3.77-3.70(m,2H),3.67-3.57(m,2H),2.96-2.91(m,2H),2.56-2.50(m,4H),2.17(s,6H),2.06-1.96(m,4H),1.85-1.59(m,26H),1.19-0.95(m,16H)。
LCMS(ESI,m/z):[M+H]+=803.3.1H NMR(300 MHz,DMSO-d6):δ 8.80-8.30(m,2H),8.10-7.90(m,2H),7.30-7.11(m,2H),7.03-6.96(m,2H),6.95-6.80(m,2H),5.12-4.99(m,2H),4.68-4.52(m,2H),4.50-4.26(m,2H),4.18-3.98(m,4H),3.70-3.52(m,4H),3.01-2.88(m,2H),2.22-2.19(m,6H),2.13-1.80(m,12H),1.32-1.17(m,6H),1.16-1.02(m,6H)。
LCMS(ESI,m/z):[M+H]+=831.4.1H NMR(300 MHz,DMSO-d6):δ 8.83-8.35(m,2H),8.10-7.80(m,2H),7.41-7.12(m,2H),7.02-6.96(m,2H),6.95-6.80(m,2H),5.15-4.92(m,2H),4.59-4.25(m,4H),4.18-3.85(m,4H),3.78-3.48(m,4H),3.03-2.90(m,2H),2.25-2.18(m,6H),2.16-1.92(m,6H),1.91-1.70(m,8H),1.68-1.48(m,2H),1.18-1.02(m,6H),0.96-0.78(m,6H)。
LCMS(ESI,m/z):[M+H]+=859.4。1H NMR(300 MHz,DMSO-d6):δ 8.52-8.37(m,2H),7.97-7.88(m,2H),7.25-7.12(m,2H),7.08-6.96(m,2H),6.95-6.80(m,2H),5.12-4.94(m,2H),4.57-4.40(m,2H),4.39-4.24(m,2H),4.18-4.05(m,4H),3.79-3.56(m,4H),3.04-2.91(m,2H),2.24-2.17(m,6H),2.15-1.75(m,16H),1.21-1.09(m,6H),1.00-0.80(m,12H)。
LCMS(ESI,m/z):[M+H]+=887.4.1H NMR(300 MHz,DMSO-d6):δ 8.70-8.42(m,2H),7.96-7.70(m,2H),7.25-7.20(m,2H),7.05-6.93(m,2H),6.87-6.78(m,2H),5.14-4.82(m,2H),4.67-4.50(m,2H),4.45-4.26(m,2H),4.19-4.10(m,4H),3.81-3.60(m,4H),3.07-2.85(m,2H),2.38-2.15(m,8H),2.14-1.94(m,6H),1.93-1.71(m,6H),1.23-1.09(m,6H),1.08-0.97(m,16H),0.95-0.92(m,2H)。
LCMS(ESI,m/z):[M+H]+=855.4.1H NMR(300 MHz,DMSO-d6):δ 8.80-8.28(m,2H),8.06-7.80(m,2H),7.38-7.12(m,2H),7.05-6.96(m,2H),6.95-6.80(m,2H),5.12-4.94(m,2H),4.57-4.36(m,2H),4.31-4.25(m,2H),4.20-4.00(m,4H),3.72-3.56(m,4H),3.05-2.94(m,2H),2.24-2.19(m,6H),2.13-1.95(m,6H),1.93-1.78(m,6H),1.25-1.05(m,8H),0.57-0.25(m,8H)。
LCMS(ESI,m/z):[M+H]+=911.5.1H NMR(300 MHz,DMSO-d6):δ 8.75-8.26(m,2H),8.08-7.80(m,2H),7.52-7.14(m,2H),7.08-6.96(m,2H),6.95-6.80(m,2H),5.12-4.90(m,2H),4.63-4.45(m,2H),4.37-4.31(m,2H),4.21-3.96(m,4H),3.80-3.58(m,4H),3.05-2.90(m,2H),2.35-1.95(m,16H),1.94-1.76(m,6H),1.75-1.45(m,12H),1.39-1.21(m,4H),1.19-1.00(m,6H)。
LCMS(ESI,m/z):[M+H]+=827.4.1H NMR(300 MHz,DMSO-d6):δ 8.38-8.20(m,2H),8.01-7.85(m,2H),7.33-7.21(m,4H),7.20-7.03(m,2H),5.43-5.25(m,2H),4.52-4.41(m,2H),4.39-4.23(m,2H),3.80-3.58(m,4H),3.05-2.92(m,2H),2.90-2.71(m,2H),2.64-2.55(m,2H),2.44-2.16(m,10H),2.15-1.95(m,6H),1.93-1.66(m,6H),1.18-1.05(m,6H),1.02-0.82(m,12H)。
LCMS(ESI,m/z):[M+H]+=799.6.1H NMR(300 MHz,DMSO-d6)δ 8.64-8.15(m,2H),8.10-7.91(m,2H),7.36-7.15(m,4H),6.97-6.82(m,2H),5.05-4.93(m,2H),4.68-4.52(m,2H),4.43-4.28(m,2H),3.72-3.47(m,4H),3.01-2.89(m,2H),2.38-2.25(m,3H),2.26-2.17(m,7H),2.17-1.53(m,18H),1.29-1.18(m,6H),1.16-1.05(m,6H)。
LCMS(ESI,m/z):[M+H]+=827.5.1H NMR(300 MHz,DMSO-d6)δ 8.33-8.19(m,3H),8.19-7.95(m,2H),7.32-7.15(m,4H),6.96-6.81(m,2H),5.03-4.97(m,2H),4.60-4.47(m,2H),4.42-4.30(m,2H),3.77-3.55(m,4H),3.21-3.08(m,2H),2.35-2.20(m,9H),2.16-1.95(m,5H),1.95-1.51(m,16H),1.22-1.06(m,6H),0.97-0.80(m,6H)。
LCMS(ESI,m/z):[M+H]+=883.6.1H NMR(300 MHz,DMSO-d6):δ:8.42-8.35(m,2H),7.89-7.80(m,2H),7.39-7.35(m,2H),7.18-7.13(m,2H),6.92-6.84(m,2H),5.02-4.95(m,2H),4.60-4.53(m,2H),4.37-4.33(m,2H),3.80-3.65(m,4H),3.03-2.96(m,2H),2.42-1.98(m,16H),1.85-1.64(m,12H),1.17-0.93(m,24H)。
LCMS(ESI,m/z):[M+H]+=939.6.1H NMR(300 MHz,DMSO-d6)δ 8.56-8.25(m,2H),8.03-7.93(m,2H),7.36-7.25(m,2H),7.25-7.12(m,2H),6.95-6.81(m,2H),5.05-4.89(m,2H),4.61-4.44(m,2H),4.40-4.26(m,2H),3.97-3.56(m,8H),3.30-3.18(m,4H),3.03-2.90(m,2H),2.38-1.92(m,18H),1.90-1.69(m,10H),1.68-1.50(m,6H),1.42-1.18(m,4H),1.18-1.05(m,6H)。
LCMS(ESI,m/z):[M+H]+=967.7.1H NMR(300 MHz,DMSO-d6):δ 8.49-8.33(m,2H),8.01-7.88(m,2H),7.41-7.30(m,2H),7.28-7.15(m,2H),6.96-6.77(m,2H),5.59-5.45(m,2H),5.13-4.92(m,2H),4.49-4.30(m,4H),4.29-4.15(m,2H),3.99-3.85(m,2H),3.55-3.43(m,2H),3.03-2.91(m,2H),2.38-2.28(m,4H),2.23-2.11(m,8H),1.98-1.47(m,24H),1.24-0.96(m,16H)。
LCMS(ESI,m/z):[M+H]+=855.7.1H NMR(300 MHz,DMSO-d6):δ 8.59-8.22(m,2H),8.00-7.76(m,2H),7.60-7.29(m,2H),7.28-7.13(m,2H),6.97-6.82(m,2H),5.09-4.91(m,2H),4.54-4.30(m,4H),3.86-3.57(m,4H),3.08-2.91(m,2H),2.39-1.98(m,18H),1.94-1.57(m,12H),1.21-1.08(m,6H),1.04-0.80(m,12H)。
LCMS(ESI,m/z):[M+H]+=935.8.1H NMR(300 MHz,DMSO-d6)δ 8.33-8.20(m,2H),7.97-7.87(m,2H),7.35-7.28(m,2H),7.24-7.14(m,2H),6.97-6.83(m,2H),5.09-4.91(m,2H),4.51-4.41(m,2H),4.40-4.28(m,2H),3.83-3.70(m,2H),3.68-3.58(m,2H),3.04-2.90(m,2H),2.40-2.31(m,1H),2.27-2.13(m,8H),2.11-1.96(m,6H),1.91-1.53(m,25H),1.25-0.92(m,16H)。
[M+H]+=799.4。1H NMR(300 MHz,DMSO-d6):δ 8.34-8.17(m,2H),8.08-7.93(m,2H),7.45-7.21(m,4H),7.19-7.08(m,2H),5.42-5.27(m,2H),4.61-4.50(m,2H),4.38-4.30(m,2H),3.78-3.56(m,4H),3.02-2.92(m,2H),2.90-2.77(m,2H),2.62-2.56(m,2H),2.38-2.28(m,2H),2.25-2.17(m,7H),2.16-1.98(m,5H),1.93-1.69(m,8H),1.66-1.50(m,2H),1.16-1.07(m,6H),0.96-0.82(m,6H)。
LCMS(ESI,m/z):[M+H]+=939.6.1H NMR(300 MHz,DMSO-d6):δ 8.74-8.33(m,2H),7.98-7.73(m,2H),7.55-7.12(m,2H),7.08-6.98(m,2H),6.97-6.82(m,2H),5.13-4.92(m,2H),4.56-4.25(m,4H),4.21-3.99(m,4H),3.83-3.58(m,4H),3.06-2.91(m,2H),2.28-2.15(m,6H),2.14-1.96(m,6H),1.96-1.40(m,20H),1.29-0.89(m,16H)。
LCMS(ESI,m/z):[M+H]+=943.5.1H NMR(300 MHz,DMSO-d6):δ 8.78-8.33(m,2H),8.07-7.75(m,2H),7.59-7.10(m,2H),7.07-6.98(m,2H),6.94-6.83(m,2H),5.10-4.89(m,2H),4.60-4.42(m,2H),4.39-4.27(m,2H),4.22-4.00(m,4H),3.93-3.63(m,8H),3.25-3.17(m,2H),3.02-2.92(m,2H),2.27-1.69(m,24H),1.68-1.52(m,2H),1.52-0.99(m,12H)。
LCMS(ESI,m/z):[M+H]+=911.6.1H NMR(300 MHz,DMSO-d6):δ 8.61-8.20(m,2H),8.08-7.81(m,2H),7.27-7.25(m,4H),7.15-7.12(m,2H),5.35-5.32(m,2H),4.54-4.48(m,2H),4.34-4.30(m,2H),3.85-3.69(m,7H),3.41-3.36(m,2H),3.31-3.19(m,4H),2.99-2.97(m,2H),2.85-2.73(m,2H),2.61-2.55(m,2H),2.40-2.00(m,15H),1.89-1.56(m,10H),1.48-1.18(m,4H),1.11(d,J=6.6 Hz,6H)。
LCMS(ESI,m/z):[M+H]+=954.0.1H NMR(300 MHz,DMSO-d6):δ 8.22(d,J=8.7 Hz,2H),7.98(d,J=8.7 Hz,2H),7.11-6.95(m,2H),6.88(d,J=7.5 Hz,2H),6.59(d,J=7.5 Hz,2H),6.50(s,1H),4.99-4.85(m,2H),4.56-4.44(m,2H),4.41-4.27(m,2H),3.91-3.68(m,8H),3.32-3.17(m,5H),3.06-2.92(m,2H),2.22-2.17(m,7H),2.15-1.52(m,24H),1.28-1.09(m,12H)。
LCMS(ESI,m/z):[M+H]+=870.6.1H NMR(300 MHz,DMSO-d6):δ 8.23(d,J=8.7 Hz,2H),7.95(d,J=9.0 Hz,2H),7.07-6.86(m,4H),6.64-6.54(m,2H),6.50(s,1H),5.00-4.90(m,2H),4.50-4.28(m,4H),3.79-3.56(m,4H),3.10-2.96(m,3H),2.60-2.54(m,3H),2.23-2.16(m,7H),2.14-1.94(m,6H),1.91-1.51(m,13H),1.20-1.07(m,6H),1.01-0.77(m,12H)。
LCMS(ESI,m/z):[M+H]+=842.5.1H NMR(300 MHz,DMSO-d6):δ 8.62-7.95(m,6H),7.07-6.95(m,2H),6.88-6.85(m,2H),6.63-6.48(m,3H),5.02-4.90(m,2H),4.59-4.46(m,3H),4.38-4.29(m,3H),3.73-3.58(m,5H),3.15-3.05(m,2H),2.30-2.21(m,6H),2.12-1.50(m,21H),1.22-1.10(m,6H),0.96-0.77(m,6H)。
LCMS(ESI,m/z):[M+H]+=898.6.1H NMR(300 MHz,DMSO-d6):δ 9.66(s,1H),8.31-8.28(m,2H),8.05-7.95(m,2H),7.41-7.35(m,2H),7.29-7.13(m,4H),5.05-4.90(m,2H),4.47-4.42(m,2H),4.34-4.31(m,2H),3.72-3.62(m,4H),3.05-2.95(m,3H),2.90-2.86(m,2H),2.73-2.69(m,2H),2.19(s,6H),2.10-1.60(m,19H)1.19-1.11(m,6H),0.97-0.80(m,12H)。
LCMS(ESI,m/z):[M+H]+=982.5.1H NMR(300 MHz,DMSO-d6):δ 9.66(s,1H),8.37-8.25(m,2H),8.02-7.93(m,2H),7.42-7.11(m,6H),5.03-4.91(m,2H),4.56-4.45(m,2H),4.43-4.27(m,2H),3.91-3.59(m,8H),3.28-3.18(m,4H),3.03-2.87(m,4H),2.73-2.69(m,2H),2.24-1.52(m,30H),1.40-1.24(m,4H),1.22-1.06(m,6H)。
LCMS(ESI,m/z):[M+H]+=870.5.1H NMR(300 MHz,DMSO-d6):δ 9.67(s,1H),8.30-8.20(m,2H),8.03-7.93(m,2H),7.41-7.03(m,6H),5.05-4.93(m,2H),4.58-4.48(m,2H),4.40-4.26(m,2H),3.73-3.57(m,3H),3.02-2.83(m,4H),2.76-2.67(m,2H),2.26-2.15(m,6H),2.13-1.49(m,23H),1.19-1.06(m,6H),0.96-0.76(m,6H)。
LCMS(ESI,m/z):[M+H]+=926.7.1H NMR(300 MHz,DMSO-d6):δ 9.60(s,1H),8.37-8.34(m,2H),7.87-7.70(m,2H),7.70-7.12(m,6H),4.99-4.91(m,2H),4.59-4.53(m,2H),4.35-4.32(m,2H),3.74-3.64(m,4H),3.00-2.83(m,4H),2.72-2.65(m,2H),2.47-2.00(m,12H),1.99-1.65(m,12H),1.17-1.11(m,6H),1.01-0.91(m,18H)。
LCMS(ESI,m/z):[M+H]+=982.4.1H NMR(300 MHz,DMSO-d6):δ 10.60(m,1H),8.78-8.42(m,1H),8.39-8.30(m,2H),8.04-7.95(m,1H),7.94-7.68(m,2H),7.52-7.44(m,1H),7.17-6.84(m,3H),5.29-4.89(m,2H),4.66-4.22(m,8H),3.84-3.45(m,4H),3.06-2.88(m,2H),2.34-1.44(m,32H),1.34-0.84(m,16H)。
LCMS(ESI,m/z):[M+H]+=950.5.1H NMR(300 MHz,DMSO-d6):δ 9.78(s,1H),8.27-8.20(m,2H),7.92-7.88(m,2H),7.62-7.59(m,1H),7.42-7.40(m,2H),7.33-7.31(m,1H),7.21-7.16(m,1H),7.11-7.09(m,1H),5.35-5.21(m,2H),4.45-4.30(m,4H),3.77-3.65(m,4H),3.22-3.16(m,2H),2.99-2.94(m,4H),2.83-2.72(m,1H),2.40-2.34(m,3H),2.22-2.18(m,6H),2.08-2.02(m,4H),1.84-1.61(m,18H),1.22-0.98(m,16H)。
LCMS(ESI,m/z):[M+H]+=1019.8.1H NMR(300 MHz,DMSO-d6)δ 8.26-8.10(m,2H),7.90-7.78(m,2H),7.03-6.78(m,6H),5.00-4.76(m,2H),4.53-4.35(m,2H),4.35-4.21(m,2H),4.07-3.50(m,4H),3.31-3.18(m,7H),2.99-2.95(m,2H),2.73-2.64(m,4H),2.28-2.17(m,7H),2.17-1.99(m,4H),1.84-1.50(m,25H),1.20-0.93(m,17H)。
LCMS(ESI,m/z):[M+H]+=1019.8。1H NMR(300 MHz,DMSO-d6)δ 7.99(d,J=9.0 Hz,2H),7.86(d,J=9.0 Hz,2H),7.11(d,J=8.4 Hz,2H),6.84-6.75(m,2H),6.68(s,2H),4.95-4.77(m,2H),4.55-4.42(m,2H),4.37-4.23(m,2H),3.78-3.56(m,4H),3.29-3.18(m,8H),3.02-2.91(m,2H),2.78-2.65(m,4H),2.17(s,6H),2.11-1.95(m,4H),1.94-1.46(m,26H),1.24-0.89(m,16H)。
LCMS(ESI,m/z):[M+H]+=1019.8。1H NMR(400 MHz,CDCl3):δ 7.61(s,2H),7.15-7.07(m,4H),6.98-6.95(m,4H),5.14(s,2H),4.63-4.51(m,4H),3.85-3.81(m,2H),3.63-3.53(m,2H),3.10-2.95(m,10 H),2.86-2.82(m,2H),2.72-2.66(m,2H),2.57-2.48(m,2H),2.35(s,6H),2.16-1.95(m,6H),1.93-1.76(m,8H),1.66-1.57(m,12H),1.28-1.24(m,8H),1.13-0.88(m,10H)。
LCMS(ESI,m/z):[M+H]+=967.6。1H NMR(400MHz,CDCl3):δ 7.76(m,2H),7.20-6.94(m,8H),5.21-5.07(m,2H),4.63-4.57(m,2H),4.42-4.40(m,1H),3.63-4.40(m,4H),3.01-2.83(m,10H),2.80-2.70(m,4H),2.48-2.32(m,8H),2.18-1.93(m,8H),1.78-1.53(m,6H),1.32-1.30(m,3H),1.21-0.99(m,18H),0.89-0.82(m,6H)。
LCMS(ESI,m/z):[M+H]+=843.5.1H NMR(300 MHz,DMSO-d6):δ 8.25(d,J=8.7 Hz,2H),7.97(d,J=8.1 Hz,2H),7.25-7.01(m,4H),6.62-6.52(m,2H),5.04-4.93(m,2H),4.59-4.41(m,2H),4.41-4.28(m,2H),3.75-3.48(m,4H),3.02-2.88(m,2H),2.68-2.57(m,4H),2.18(s,6H),2.15-1.44(m,22H),1.16-1.06(m,6H),0.94-0.76(m,6H)。
LCMS(ESI,m/z):[M+H]+=871.6.1H NMR(300 MHz,DMSO-d6):δ 8.30-8.25(m,2H),7.95-7.92(m,2H),7.11-7.04(m,4H),6.58-6.55(m,2H),5.03-4.95(m,2H),4.47-4.42(m,2H),4.34-4.30(m,2H),3.77-3.62(m,4H),3.06-2.92(m,2H),2.67-2.60(m,4H),2.22-2.18(m,6H),2.09-1.96(m,7H),1.88-1.78(m,9H),1.72-1.62(m,4H),1.16-1.10(m,6H),0.95-0.80(m,12H)。
LCMS(ESI,m/z):[M+H]+=955.6.1H NMR(300 MHz,DMSO-d6):δ 8.53-8.01(m,5H),7.40-7.00(m,4H),6.61-6.54(m,2H),5.06-4.90(m,2H),4.56-4.46(m,3H),4.37-4.26(m,3H),3.89-3.57(m,11H),3.34-3.13(m,6H),2.68-2.59(m,3H),2.30-2.21(m,6H),2.14-1.51(m,20H),1.42-1.21(m,4H),1.21-1.06(m,6H)。
アッセイプロトコル
IAPは、がんの発生の主な原因の1つであり、抗アポトーシスタンパク質の過剰発現に起因し得る。このプロトコルは、FP(蛍光偏光)技術を使用して、XIAP Bir3ドメイン、cIAP1およびcIAP2の3つの結合アッセイを確立する。使用される蛍光プローブは、5-カルボキシフルオレセイン(AbuRPFK-5FAM)にコンジュゲートした合成ペプチドである。蛍光偏光値(mP)は、Envisionによって検出され、タンパク質および蛍光マーカーの結合度を反映するために使用された。
a.適切な試験管で最終化合物濃度の100倍を調製し、5uLの化合物を、10%DMSOを含む45μLの1X反応緩衝液に移す。
本明細書に記載の本技術の化合物は、上記のプロトコルに従って試験されたか、または試験され、上記のアッセイの1つ以上において1uM以下のIC50値を示すか、または示すと予想される。ある特定の化合物は、100nM以下のIC50を示すか、または示すことが期待され、他の化合物は、上記の結合アッセイのうちの1つ以上において、10nM以下のIC50を示すか、または示すと予想される。選択された化合物の例示的な結果を、表5に示す。
ある特定の実施形態を図示し、説明してきたが、当業者は、前述の明細書を読んだ後、本明細書に記載される本技術の化合物もしくは塩、薬学的組成物、誘導体、プロドラッグ、代謝産物、その互変異性体もしくはラセミ混合物に対する変更、同等物の置換、および他の種類の改変をもたらすことができる。上記の各態様および実施形態は、他の態様および実施形態のいずれかまたは全てに関して開示されたそのような変形または態様もそこに含むかまたは組み込むことができる。
Claims (21)
- 式Iの化合物、その立体異性体、または前記化合物もしくは前記化合物の前記立体異性体の薬学的に許容される塩であって、
式中、
Xが、O、NR6、またはCH2であり、
qが、0、1、または2であり、
R1およびR2が、各出現において、独立して、置換もしくは非置換のC1~6アルキル、C3~6シクロアルキル、アリール、アラルキル、ヘテロシクリル、またはヘテロシクリルアルキル基から選択され、
R3およびR4が、各出現において、独立して、H、アミノ保護基、または置換もしくは非置換のC1~6アルキル基であり、
R5が、各出現において、独立して、H、F、NH2、OH、NH-(アミノ保護基)、またはO-(ヒドロキシル保護基)であり、
R6が、各出現において、独立して、H、置換もしくは非置換のC1~6アルキル、C3~6シクロアルキル基、またはアミノ保護基であり、
リンカーが、結合、オキシ部分、または、アミノ、アルキレン、ヘテロアルキレン、アルケニレン、ヘテロアルケニレン、アルキニレン、ヘテロアルキニレン、シクロアルキレン、シクロアルキルヘテロアルキレン、アリーレン、アラルキレン、アリールヘテロアルキレン、ヘテロシクリルアルキレン、ヘテロシクリルヘテロアルキレン、ヘテロアリーレン、ヘテロアリールアルキレン、およびヘテロアリールヘテロアルキレンからなる群から選択される置換されていてもよい部分から選択される二価部分である、
式Iの化合物、その立体異性体、または前記化合物もしくは前記化合物の前記立体異性体の薬学的に許容される塩。 - リンカーが、ヘテロアルキレン、アリーレン、アラルキレン、アリールヘテロアルキレン、ヘテロシクリルアルキレン、およびヘテロシクリルヘテロアルキレンからなる群から選択される、請求項1に記載の化合物。
- リンカーが、C2~C12ポリアルキレンオキシド、フェニルアルキレン、フェニルヘテロアルキレン、ピペラジニルアルキレン、およびピペラジニルヘテロアルキレンからなる群から選択される、請求項1または請求項2に記載の化合物。
- nが、1、2、または3であり、mが、0、1、2、3、または4である、請求項4に記載の化合物。
- リンカーが、結合、-NH-、または-C(O)NH-である、請求項1~5のいずれか1項に記載の化合物。
- mが、1、2、3、または4である、請求項8に記載の化合物。
- nが、2または3である、請求項10に記載の化合物。
- R1およびR2が、独立して、メチル、エチル、n-プロピル、i-プロピル、n-ブチル、s-ブチル、i-ブチル、t-ブチル、シクロプロピル、シクロブチル、シクロヘキシル、およびシクロペンチル基からなる群から選択される、および/または
R3が、メチル、エチル、n-プロピル、i-プロピル、n-ブチル、i-ブチル、またはt-ブチル基である、および/または
R4が、アミノ保護基またはHである、および/または
R5が、Hである、および/または
Xが、CH2またはOである、および/または
qが、0または1である、
請求項1~12のいずれか1項に記載の化合物。 - R2が、メチルである、および/または
R1が、シクロヘキシルまたはイソプロピルである、および/または
R3が、メチルである、および/または
R4が、Hである、および/または
R5が、Hである、
請求項14に記載の化合物。 - 請求項1~16のいずれか1項に記載の化合物と、薬学的に許容される担体とを含む、組成物。
- IAPによって媒介されるがんまたはウイルス感染を治療するための、請求項1~16のいずれか1項に記載の化合物の有効量を含む、薬学的組成物。
- IAPによって媒介される前記がんまたはウイルス感染が、卵巣がん、卵管がん、腹膜がん、およびB型肝炎感染からなる群から選択される、請求項18に記載の薬学的組成物。
- IAPによって媒介されるがんまたはウイルス感染に罹患している対象を治療するための薬学的組成物であって、請求項1~16のいずれか1項に記載の化合物の有効量を含む、薬学的組成物。
- 前記がんまたはウイルス感染が、卵巣がん、卵管がん、腹膜がん、およびB型肝炎感染からなる群から選択される、請求項20に記載の薬学的組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962830031P | 2019-04-05 | 2019-04-05 | |
US62/830,031 | 2019-04-05 | ||
US201962831155P | 2019-04-08 | 2019-04-08 | |
US62/831,155 | 2019-04-08 | ||
PCT/US2020/026220 WO2020206000A1 (en) | 2019-04-05 | 2020-04-01 | Bivalent antagonists of inhibitors of apoptosis proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022523882A JP2022523882A (ja) | 2022-04-26 |
JP7455141B2 true JP7455141B2 (ja) | 2024-03-25 |
Family
ID=70465441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021560419A Active JP7455141B2 (ja) | 2019-04-05 | 2020-04-01 | アポトーシスタンパク質の阻害剤の二価拮抗薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220220152A1 (ja) |
EP (1) | EP3946607A1 (ja) |
JP (1) | JP7455141B2 (ja) |
KR (1) | KR20220012844A (ja) |
CN (1) | CN113677399A (ja) |
AU (1) | AU2020252216A1 (ja) |
CA (1) | CA3136106A1 (ja) |
WO (1) | WO2020206000A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512719A (ja) | 2005-10-25 | 2009-03-26 | アエゲラ セラピューティクス インコーポレイテッド | Iapbirドメイン結合化合物 |
JP2009529544A (ja) | 2006-03-16 | 2009-08-20 | アエゲラ セラピューティクス インコーポレイテッド | Iapのbirドメインに結合する化合物 |
JP2009530424A (ja) | 2006-03-21 | 2009-08-27 | ジョイアント ファーマスーティカルズ、インク. | 小分子アポトーシスプロモーター |
JP2010523717A (ja) | 2007-04-12 | 2010-07-15 | ジョイアント ファーマスーティカルズ、インク. | 抗癌剤として有用なsmac模倣二量体及び三量体 |
JP2013509429A (ja) | 2009-10-28 | 2013-03-14 | ジョイアント ファーマスーティカルズ、インク. | 二量体Smac模倣薬 |
WO2019023275A1 (en) | 2017-07-25 | 2019-01-31 | Hepagene Therapeutics, Inc. | PEPTIDE INHIBITORS DIMERS OF APOPTOSIS PROTEINS |
-
2020
- 2020-04-01 KR KR1020217035798A patent/KR20220012844A/ko unknown
- 2020-04-01 US US17/601,403 patent/US20220220152A1/en active Pending
- 2020-04-01 WO PCT/US2020/026220 patent/WO2020206000A1/en unknown
- 2020-04-01 EP EP20722071.6A patent/EP3946607A1/en active Pending
- 2020-04-01 CA CA3136106A patent/CA3136106A1/en active Pending
- 2020-04-01 AU AU2020252216A patent/AU2020252216A1/en active Pending
- 2020-04-01 CN CN202080027496.5A patent/CN113677399A/zh active Pending
- 2020-04-01 JP JP2021560419A patent/JP7455141B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512719A (ja) | 2005-10-25 | 2009-03-26 | アエゲラ セラピューティクス インコーポレイテッド | Iapbirドメイン結合化合物 |
JP2009529544A (ja) | 2006-03-16 | 2009-08-20 | アエゲラ セラピューティクス インコーポレイテッド | Iapのbirドメインに結合する化合物 |
JP2009530424A (ja) | 2006-03-21 | 2009-08-27 | ジョイアント ファーマスーティカルズ、インク. | 小分子アポトーシスプロモーター |
US20120082640A1 (en) | 2006-03-21 | 2012-04-05 | Hanson Gunnar J | Small molecule apoptosis promoters |
JP2010523717A (ja) | 2007-04-12 | 2010-07-15 | ジョイアント ファーマスーティカルズ、インク. | 抗癌剤として有用なsmac模倣二量体及び三量体 |
JP2013509429A (ja) | 2009-10-28 | 2013-03-14 | ジョイアント ファーマスーティカルズ、インク. | 二量体Smac模倣薬 |
WO2019023275A1 (en) | 2017-07-25 | 2019-01-31 | Hepagene Therapeutics, Inc. | PEPTIDE INHIBITORS DIMERS OF APOPTOSIS PROTEINS |
Also Published As
Publication number | Publication date |
---|---|
CA3136106A1 (en) | 2020-10-08 |
CN113677399A (zh) | 2021-11-19 |
EP3946607A1 (en) | 2022-02-09 |
AU2020252216A1 (en) | 2021-11-04 |
JP2022523882A (ja) | 2022-04-26 |
KR20220012844A (ko) | 2022-02-04 |
WO2020206000A1 (en) | 2020-10-08 |
US20220220152A1 (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2964945T3 (es) | Compuestos heterocíclicos que contienen nitrógeno como moduladores de FXR | |
US20030232832A1 (en) | Pyrrolotriazinone compounds and their use to teat diseases | |
CA2917964A1 (en) | Ido inhibitors | |
AU2020413997A1 (en) | Pyridazinyl-thiazolecarboxamide compound | |
WO2013106646A2 (en) | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase | |
JP7271540B2 (ja) | Ask1阻害剤としての尿素誘導体 | |
US10532999B2 (en) | 6-substituted quinazolinone inhibitors | |
KR20180021820A (ko) | Ido 억제제 | |
CA2871453A1 (en) | Quinazolinedione derivative | |
JP6903663B2 (ja) | アルキルジヒドロキノリンスルホンアミド化合物 | |
JP7455141B2 (ja) | アポトーシスタンパク質の阻害剤の二価拮抗薬 | |
US9926275B2 (en) | Allosteric modulators of the cannabinoid 1 receptor | |
WO2018028491A1 (zh) | 吲哚胺2,3-双加氧酶抑制剂及其在药学中的用途 | |
US11203592B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
US20210371459A1 (en) | Dimeric peptide inhibitors of apoptosis proteins | |
CN109689661B (zh) | 髓过氧化物酶的大环抑制剂 | |
WO2023098882A1 (en) | Methods of synthesis of chiral 3, 5-disubstituted morpholine compounds and intermediates useful therein | |
WO2023025256A1 (zh) | 一种适合作为抗体偶联药物效应分子的sting激动剂 | |
KR101162100B1 (ko) | 세포사멸 유도 활성을 갖는 신규 피라지논 유도체 및 이를 활성성분으로 포함하는 약학 조성물 | |
CN118317943A (en) | Synthesis method of chiral 3, 5-disubstituted morpholine compound and useful intermediate thereof | |
Mishra et al. | Grp94 selective inhibitors and uses thereof | |
KR20190032534A (ko) | C5a 수용체 길항제로서의 시클릭 펩티드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220407 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230113 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240229 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240312 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7455141 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |